Novartis' Certican succeeds in liver transplant trial Reuters India The trial evaluated the introduction of Certican (everolimus) with reduced exposure of another immunosuppressive drug tacrolimus administered twice-daily starting one month after liver transplantation versus standard-exposure tacrolimus, Novartis said. NOVARTIS AG : Novartis new two-year data with CerticanĀ® shows positive ... |
